highlight top-read differenti piec april provid
updat view feedback highlight includ comprehens coverag
treatment vaccin develop detail review remdesivir
work broader sector impact survey aducanumab
coronaviru treatment vaccin tracker
releas detail niaid studi impress
role help treat amelior global pandem remain
forefront investor mind pandem progress continu tri make sens
treatment vaccin develop track credibl clinic
preclin program consist receiv posit feedback investor may use
opportun find new biotech interest pipelin program evalu far along
top treatment option respect market impact take broader macro prospect
product sector believ emerg data coalescenc around viewpoint hcq
effect correspond notic shift investor inbound hcq
drop substanti note investor interest late trend toward immun modul
kevzara acterma -- expect addit data may cours biggest piec
news treatment front sudden delug remdesivir clinic data culmin
eua fda -- see hope step though continu believ unlik
dramat chang cours pandem note suppli limit uncertain monet
potenti remain headwind still data come
get back fundament corona curv market stabil
coverag coronaviru also extend broader sector impact expect see well
long term fallout pandem impact sector mani way biotech
cope challeng clinic trial enrol virtual launch also potenti experi
near-term tailwind inventori stockpil prior buy-sid survey suggest increas
investor focu compani balanc sheet catalyst outlook put togeth
detail sector report well revis mani estim ahead street factor
latest think around pandem acknowledg sector retain defens qualiti
believ impact earn timelin continu underappreci continu
felt back-half year beyond
continu next page
price prior trade day market close estimate unless otherwis note
valu usd unless otherwis note
capit market appreci consider institut investor all-america research survey
continu cover
impact cont continu see investor split bullish recoveri
time resolut pandem vs cautious high likelihood
linger societ impact given treatment may increment effect vaccin could
still way
question answer adu file delay
buy-sid survey show grow skeptic see fda scrutin adu still major upsid
stat scienc histori unravel adu mysteri top thing chang sinc jan
biggest news earn far aducanumab delay investor shown
increas cautious despit earn beat believ
larg due increasingli vagu aducanumab timelin latest survey find
investor believ approv chanc dip vs prior
highlight number factor may led delay fda conduct
addit analysi imput sub-popul engag studi failur continu
take conserv approach aducanumab see ultim opportun
out-year sale po note core busi remain solid
believ survey anecdot feedback investor increasingli stay
away stori given adu regulatori tecfidera ip risk
top-read/most differenti note april includ
asid remdesivir one talked-about drug coverag
major data readout eha month lay believ bar
expect see
often hear investor compar gene therapi program see
posit readthrough recent earn call despit potenti competit
receiv major pushback follow downgrad given
stock run though investor speak continu skew favor name given
low-risk growth profil pipelin option still look greater pipelin de-
risk help share break new rang howev
question answer adu file delay
stat scienc histori unravel adu mysteri top thing chang sinc jan
buy-sid survey show grow skeptic see fda scrutin adu still major upsid hope
abraham takeaway final day
renza takeaway third doctor day apto
earn preview select biotech coronaviru storm
biotech realiti check project catalyst calendar look like adjust
get back fundament corona curv market stabil
earn preview street underestim impact rev ep
refresh thesi market start look past corona oversold despit lt mf opportun
coronaviru treatment vaccin tracker updat
coronaviru could underappreci neg long-term impact drug price
take hydroxychloroquin debat
coronaviru treatment vaccin tracker updat
coronaviru treatment vaccin tracker updat
on-the-ground look develop drug
coronaviru treatment vaccin tracker updat
data preview look upcom sever remdesivir trial readout
coronaviru treatment vaccin tracker updat perspect updat
refresh thesi market start look past corona like setup lena make-or-break year
refresh thesi market start look past corona hcv pipelin slowdown
nash track shtg delay new pc data continu valid mechan
new remdesivir compassion use data continu keep aliv
refresh thesi market start look past corona hiv resili option
uncov second studi remdesivir china suspend continu expect
data come week
report remdesivir data look encourag surfac mani unknown
investor kol feedback emerg remdesivir data implic new expans
clariti hazard ratio suggest favor remdesivir trend question still linger
learn just-publish china sever remdesivir data
remdesivir data emerg lancet post china sever studi
refresh thesi market start look past corona stock bounceback miss risk
refresh thesi market start look past corona lay groundwork nash opportun
detail ain/vin interim data asccp add context profil
ind accept mark key expect step vaccin
program set clinic entri
refresh thesi market start look past corona caplyta differenti under-valued
luma luma yay/nay studi author provid answer debat caplyta effect size
refresh thesi market start look past corona xpovio pois futur inflect
biotech lit bit review interest literatur scienc
fda continu time ongenti approv morn
refresh thesi market start look past corona pipelin promis re-affirmed
bleed edg andexxa opportun initi outperform
noteworthi weekli rx trend continu revers corona-rel stockpil
noteworthi weekli rx trend continu revers corona-rel stockpil
refresh thesi market start look past corona lt valu
oppti benefit lt mental health toll persist pandem rais
refresh thesi market start look past corona expect resurg gt enthusiasm
refresh thesi market start look past corona growth pipelin creat qualiti hold
first take quarter trikafta expect
